Yair Lotan, MD, considers the implications of the POUT study presented at ASCO GU 2018
Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT Southwestern Medical Center, Dallas, offers opinion on the POUT study presented at ASCO GU 2018.
Yair Lotan, MD, explains how new guidelines have changed the treatment of bladder cancer
Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT Southwestern Medical Center, Dallas, tells us how the new guidelines in bladder cancer have changed treatment algorithms.
Yair Lotan, MD, regarding the role of molecular markers in high-risk bladder cancer patients
Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT Southwestern Medical Center, Dallas, elaborates on the role of molecular markers to identify high-risk bladder cancer patients that should receive multi-modality treatment.
Yair Lotan, MD, on how multi-modality treatment is being applied to locally advanced bladder cancer
Dr. Lotan, Professor, Chief of Urologic Oncology, Holder of the Helen J. and Robert S. Strauss Professorship in Urology, UT Southwestern Medical Center, Dallas, discusses how multi-modality treatment is being applied to locally advanced bladder cancer patients.
Petros Grivas, MD, PhD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, discusses whether DNA repair gene mutations have a predictive or prognostic role in metastatic urothelial carcinoma.
Petros Grivas, MD, PhD, outlines the POUT study presented at ASCO GU 2018
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, tells us about the POUT clinical study presented at ASCO GU 2018 and its implications for clinicians.
Petros Grivas, MD, PhD, discusses molecular characterization & bladder subtyping data
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, explains how molecular characterization and bladder subtyping data can be used to improve outcomes in metastatic bladder cancer.
Petros Grivas, MD, PhD, considers the role of the PD-L1 biomarker in the treatment of bladder cancer
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, shares thoughts on the usefulness of the PD-L1 biomarker in the treatment of bladder cancer.
Petros Grivas, MD, PhD, on combining immunotherapy and chemotherapy in metastatic bladder cancer
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, offers opinion on the best way to combine immunotherapy and chemotherapy in metastatic bladder cancer.
Petros Grivas, MD, PhD, regarding the role of immunotherapy in metastatic bladder cancer
Dr. Grivas, Associate Professor, Medicine Clinical Director, GU Oncology, University of Washington, elaborates on the role of immunotherapy in patients undergoing radiation therapy for the treatment of metastatic bladder cancer.
Daniel P. Petrylak, MD, on the role of DNA repair gene mutations in metastatic urothelial carcinoma
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, considers whether DNA repair gene mutations have a predictive or prognostic role in metastatic urothelial carcinoma and the implications for the future.
Daniel P. Petrylak, MD, offers opinion on the POUT study presented at ASCO GU 2018
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, elaborates on the implications of the POUT study presented at ASCO GU 2018.
Daniel P. Petrylak, MD, on molecular characterization & bladder subtyping in bladder cancer
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses how molecular characterization and bladder subtyping data can be used to improve outcomes in metastatic bladder cancer.
Daniel P. Petrylak, MD, on immunotherapy & chemotherapy combinations in metastatic bladder cancer
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, reflects on today’s evidence and offers opinion on the best way to combine immunotherapy with chemotherapy in metastatic bladder cancer.
Naomi B. Haas, MD, on how patient characteristics play a role in sequencing in metastatic RCC
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, describes how patient characteristics play a role in selecting one agent over another when sequencing for metastatic RCC patients.
Naomi B. Haas, MD, on how immunotherapies are being integrated into kidney cancer treatment
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses how immunotherapies are being integrated into the treatment of renal cell cancer.
Naomi B. Haas, MD, explains how cabozantinib is being integrated into treatment of renal cell cancer
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, tells us how cabozantinib is being integrated into the treatment of previously untreated, advanced renal cell cancer patients.
Daniel J. George, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials
Dr. George, Director, GU Oncology, Duke Cancer Institute, offers opinion on whether clinicians should be concerned about the difference in mortality in the PROSPER and SPARTAN trials presented at ASCO GU 2018.
Daniel J. George, MD, regarding the conclusions from the SPARTAN study at ASCO GU 2018
Dr. George, Director, GU Oncology, Duke Cancer Institute, elaborates on what can be concluded from SPARTAN, the Phase III study of apalutamide in men with non-metastatic castrate-resistant prostate cancer.
Peter C. Black, MD, FACS, FRCSC, outlines the results of the POUT study presented at ASCO GU 2018
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, discusses the POUT study presented at ASCO GU 2018 and the implications for practices.
Peter C. Black, MD, FACS, FRCSC, on molecular characterization & bladder subtyping data
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, elaborates on how molecular characterization and bladder subtyping data can be used to improve outcomes in metastatic bladder cancer.
Peter C. Black, MD, FACS, FRCSC, regarding checkpoint blockade in non-muscle invasive bladder cancer
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, discusses whether there is a role for checkpoint blockade in non-muscle invasive bladder cancer.
Nicholas J. Vogelzang, MD, on the benefit of adding docetaxel to 1st line, long-term hormone therapy
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, considers whether it benefits prostate cancer patients to add docetaxel to 1st line, long-term hormone therapy.
Nicholas J. Vogelzang, MD, discusses the difference in mortality in the PROSPER and SPARTAN trials
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, offers opinion on whether clinicians should be concerned about the difference in mortality in the PROSPER and SPARTAN trials.
Nicholas J. Vogelzang, MD, regarding the conclusions from the SPARTAN trial at ASCO GU 2018
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, discusses what can be concluded about SPARTAN, the Phase III study of apalutamide in men with non-metastatic, castrate-resistant prostate cancer, presented at ASCO GU 2018.
Nicholas J. Vogelzang, MD, outlines the results of the PROSPER study presented at ASCO GU 2018
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, tells us about the results of PROSPER, the Phase III study of enzalutamide in men with non-metastatic, castrate-resistant prostate cancer, presented at ASCO GU 2018.
Thomas Powles, MD, MBBS, MRCP, regarding immunotherapy & chemotherapy combinations in bladder cancer
Dr. Powles, Professor of Genitourinary Oncology (HCC), Director, Barts Cancer Center, London, England, offers opinion on the best way to combine immunotherapy and chemotherapy in advanced metastatic bladder cancer.
William K. Oh, MD, on abiraterone acetate fine particle formulation
Dr. Oh, Chief, Division of Hematology and Medical Oncology, Deputy Director, Tisch Cancer Institute, outlines abiraterone acetate fine particle formulation and how it compares with the source product abiraterone acetate.
William K. Oh, MD, discusses how PET scans are changing the way we diagnose & treat prostate cancer
Dr. Oh, Chief, Division of Hematology and Medical Oncology, Deputy Director, Tisch Cancer Institute, elaborates on how PET scans are changing the way we diagnose and treat prostate cancer.
William K. Oh, MD, considers the impact of apalutamide on M0 CRPC patients
Dr. Oh, Chief, Division of Hematology and Medical Oncology, Deputy Director, Tisch Cancer Institute, offers opinion on whether apalutamide has the potential to change the way patients with M0 CRPC are treated.
Christopher J. Kane MD, FACS, considers how radiotherapy should be applied after prostatectomy
Dr. Kane, Professor and Chair of Urology, Senior Deputy Director, Moores Comprehensive Cancer Center, UC San Diego, offers opinion on how radiotherapy should be applied after prostatectomy in prostate cancer patients.
Christopher J. Kane MD, FACS, regarding the use of neoadjuvant therapy in prostate cancer
Dr. Kane, Professor and Chair of Urology, Senior Deputy Director, Moores Comprehensive Cancer Center, UC San Diego, describes what can be concluded about the use of neoadjuvant therapy in newly diagnosed high-risk prostate cancer patients.
Christopher J. Kane MD, FACS, on how the field of imaging is evolving
Dr. Kane, Professor and Chair of Urology, Senior Deputy Director, Moores Comprehensive Cancer Center, UC San Diego, tells us where the magnetic resonance imaging field is moving in the diagnosis and treatment of prostate cancer.
Maha Hussain, MD, FACP, FASCO, offers opinion on how to avoid over-treatment and under-treatment
Dr. Hussain, Genevieve Teuton Professor of Medicine, Division of Hem/Onc, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, shares thoughts on how to avoid under-treatment and over-treatment of prostate cancer.
Maha Hussain, MD, FACP, FASCO, considers the integration of biomarkers into treatment algorithms
Dr. Hussain, Genevieve Teuton Professor of Medicine, Division of Hem/Onc, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, compares prostate cancer to other tumor types in terms of integrating biomarkers into treatment algorithms.
Maha Hussain, MD, FACP, FASCO, regarding immunotherapy & castrate-resistant prostate cancer
Dr. Hussain, Genevieve Teuton Professor of Medicine, Division of Hem/Onc, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms.
Peter C. Black, MD, FACS, FRCSC, on impact of The Cancer Genome Atlas Project in bladder cancer
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, shares how The Cancer Genome Atlas Project (TCGA) is changing the way we think about the treatment of bladder cancer.
Mark Emberton, MD, on how we avoid under diagnosing and over diagnosing in prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, explains how we can avoid under diagnosing and over diagnosing in prostate cancer.
Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, considers whether PD-L1 biomarkers are useful in the treatment of bladder cancer.
Daniel P. Petrylak, MD, outlines overall survival and immune responses from the STRIDE study
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, tells us about overall survival and immune responses with sipuleucel-T and enzalutamide from the STRIDE study presented at ASCO GU 2018.
Daniel P. Petrylak, MD, on the Phase I data of enfortumab vedotin in mUC patients from ASCO GU 2018
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, elaborates on the importance of the Phase I data of enfortumab vedotin in patients with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor failure.
Naomi B. Haas, MD, offers opinion on the optimal sequencing of agents in treatment of RCC
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses the optimal sequencing of agents in the treatment landscape for metastatic renal cell carcinoma (RCC).
Naomi B. Haas, MD, considers the role of TKIs in the treatment of renal cell cancer
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shares the latest thinking regarding TKIs in the treatment of renal cell cancer.
Naomi B. Haas, MD, on what clinical evidence can tell us about the adjuvant treatment of RCC
Dr. Haas, Director, Prostate and Kidney Cancer Program, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, elaborates on what clinical evidence tells us about the adjuvant treatment of renal cell carcinoma (RCC) patients.
Daniel J. George, MD, tells us about the results of the PROSPER study presented at ASCO GU 2018
Dr. George, Director, GU Oncology, Duke Cancer Institute, outlines the PROSPER study, a Phase III study of enzalutamide in men with non-metastatic, castrate-resistant prostate cancer, presented at ASCO GU 2018.
Daniel J. George, MD, on how genomics are being incorporated into prostate cancer treatment
Dr. George, Director, GU Oncology, Duke Cancer Institute shares thoughts on how genomics are being incorporated into the management of systemic therapy in metastatic prostate cancer.
Daniel J. George, MD, regarding toxicity concerns when using sunitinib in RCC
Dr. George, Director, GU Oncology, Duke Cancer Institute elaborates on toxicity concerns when using sunitinib in the adjuvant setting in renal cell carcinoma (RCC).
Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC
Dr. George, Director, GU Oncology, Duke Cancer Institute, considers the effectiveness of sunitinib in the adjuvant treatment of high-risk renal cell carcinoma (RCC).
Peter C. Black, MD, FACS, FRCSC, considers preferred checkpoint inhibitors for urothelial carcinoma
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, shares whether there is a preferred checkpoint inhibitor for the treatment of urothelial carcinoma and why.
Peter C. Black, MD, FACS, FRCSC, on the usefulness of molecular markers in bladder cancer treatment
Dr. Black, Senior Research Scientist, Vancouver Prostate Centre, Professor, Department of Urologic Sciences, University of British Columbia, discusses molecular markers that are useful for identifying patients and therapies for the treatment of bladder cancer.
Nicholas J. Vogelzang, MD, considers genomics and systemic therapy in advanced prostate cancer
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, elaborates on how genomics are being incorporated into the management of systemic therapy in advanced prostate cancer.
Nicholas J. Vogelzang, MD, regarding the latest trends in diagnosis of advanced prostate cancer
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, offers opinion on the latest trends in the diagnosis of advanced prostate cancer.
Nicholas J. Vogelzang, MD, on immunotherapy & prostate cancer treatment algorithms
Dr. Vogelzang, MD, Vice Chair, SWOG GU Committee Research, Medical Director, US Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, tells us how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms.
Thomas Powles, MD, MBBS, MRCP, on the evolving landscape of metastatic bladder cancer
Dr. Powles, Professor of Genitourinary Oncology (HCC), Director, Barts Cancer Center, London, England, tells us how new guidelines have influenced the evolving treatment landscape of metastatic bladder cancer.
Thomas Powles, MD, MBBS, MRCP, considers molecular markers and muscle-invasive bladder cancer
Dr. Powles, Professor of Genitourinary Oncology (HCC), Director, Barts Cancer Center, London, England, discusses how molecular markers can be used to identify high-risk muscle-invasive bladder cancer patients that require neoadjuvant therapy.
William K. Oh, MD, on biomarkers and prostate cancer treatment algorithms
Dr. Oh, Chief, Division of Hematology and Medical Oncology, Deputy Director, Tisch Cancer Institute, considers how biomarkers are being incorporated into treatment algorithms for prostate cancer.
William K. Oh, MD, regarding the results of the PROSPER and SPARTAN studies at ASCO GU 2018
Dr. Oh, Chief, Division of Hematology and Medical Oncology, Deputy Director, Tisch Cancer Institute, tells us about the results of the PROSPER and SPARTAN studies in non-metastatic castrate resistant prostate cancer presented at ASCO GU 2018.
Christopher J. Kane MD, FACS, considers how MRI is helping diagnose and treat prostate cancer
Dr. Kane, Professor and Chair of Urology, Senior Deputy Director, Moores Comprehensive Cancer Center, UC San Diego, tells us how magnetic resonance imaging is helping diagnose and treat prostate cancer.
Christopher J. Kane MD, FACS, on trends in the multimodality treatment of localized prostate cancer
Dr. Kane, Professor and Chair of Urology, Senior Deputy Director, Moores Comprehensive Cancer Center, UC San Diego, shares the latest trends in the multimodality treatment of localized prostate cancer.
Maha Hussain, MD, FACP, FASCO, on the potential impact of the PROSPER study
Dr. Hussain, Genevieve Teuton Professor of Medicine, Division of Hem/Onc, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, outlines how the PROSPER study results might impact the treatment landscape in non-metastatic castrate resistant prostate cancer.
Maha Hussain, MD, FACP, FASCO, discusses the results of the PROSPER study at ASCO GU 2018
Dr. Hussain, Genevieve Teuton Professor of Medicine, Division of Hem/Onc, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, elaborates on the results of the PROSPER study in non-metastatic castrate resistant prostate cancer.
Mark Emberton, MD, on imaging as an effective tool for diagnosing prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, outlines how imaging could be a cost-effective, long-term solution for diagnosis of prostate cancer.
Mark Emberton, MD, elaborates on the acceptance of imaging as a diagnostic tool in prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, reflects on how acceptance of imaging as a diagnostic tool in prostate cancer has changed over the last two years.
Mark Emberton, MD, describes how MRI has improved the diagnosis of prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, shares thoughts on how MRI has improved the diagnosis of prostate cancer.
Mark Emberton, MD, offers opinion on new ways to screen for prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, discusses how previous attempts at screening have forced many to consider new ways to screen for prostate cancer.
Mark Emberton, MD, regarding the evolution of imaging in localized prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, offers opinion on how imaging impacts treatment of localized prostate cancer today.
Mark Emberton, MD, considers the challenges in diagnosing men with prostate cancer
Dr. Emberton, Dean, Faculty of Medical Sciences, University College, London, elaborates on the challenges associated with diagnosing prostate cancer.
